HERBERT R. DYER, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Dr. Abruzzo's (1) editorial on auranofin oral gold is most interesting. The implication that nonrheumatologists regularly treat, rather than refer, patients with "painful and disabling synovitis" (undiagnosed) unresponsive to acetylsalicylic acid and nonsteroidal anti-inflammatory drugs is, I hope, generally false. However, if such physicians are indeed not referring these patients to a rheumatologist, Dr. Abruzzo should take a clear and unequivocal stand against this practice.
Furthermore, the notion that patients with synovitis can be relegated to an amorphous group with "early disease" is inherently objectionable. These people are seriously ill and should have the benefit of complete
DYER HR. Auranofin: A New Drug for Rheumatoid Arthritis. Ann Intern Med. ;106:631–632. doi: 10.7326/0003-4819-106-4-631
Download citation file:
Published: Ann Intern Med. 1987;106(4):631-632.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use